The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Journal: Evidence-based Cardiology. 2011;(4): 18‑25

Read: 1138 times

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

. Evidence-based Cardiology. 2011;(4):18‑25. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Close metadata

References:

  1. Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. On Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35:569-582.
  2. St John Sutton M., Pfeffer M.A., Plappert T., et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994;89:68-75.
  3. Solomon S.D., Anavekar N., Skali H., et al. Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005;112:3738-3744.
  4. St John Sutton M., Ghio S., Plappert T., et al. REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) Study Group. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation 2009;120:1858-1865.
  5. Kramer D.G., Trikalinos T.A., Kent D.M., et al. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol 2010;56:392-406.
  6. Swedberg K., Komajda M., Bohm M., et al. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial. Lancet 2010;376:875-885. Erratum in Lancet 2010;376:1988.
  7. Swedberg K., Komajda M., Bohm M., et al. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure : the Systolic Heart Failure Treatment with the I(f)Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail 2010;12:75-81.
  8. Lang R.M., Bierig M., Devereux R.B., et al. Chamber of Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463.
  9. Ceconi C., Freedman S.B., Tardif J.C., et al. BEAUTIFUL Echo-BNP Investigators. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol 2011;146:408-414.
  10. Mulder P., Barbier S., Chagraoui A., et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004;109:1674-1679.
  11. Ceconi C., Comini L., Suffredini S., et al. Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. Am J Physiol Heart Circ Physiol 2010;300:H366-H373.
  12. Dedkov E.I., Zheng W., Christensen L.P., et al. Preservation of coronary reserve by ivabradine-induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagen. Am J Physiol Heart Circ Physiol 2007;293:H590-H598.
  13. Milliez P., Messaoudi S., Nehme J., et al. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am J Physiol Heart Circ Physiol 2009;296:H435-H441.
  14. Vercauteren M., Favre J., Mulder P., et al. Protection of endothelial function by long-term heart rate reduction induced by ivabradine in a rat model of chronic heart failure. Eur Heart J 2007;28(suppl):48. P468.
  15. Gupta R.C., Wang M., Ilsar I., et al. Heart rate reduction with ivabradine improves sarcoplasmic reticulum calcium cycling in left ventricular myocardium of dogs with moderate heart failure. J Am Coll Cardiol 2011;57:E323.
  16. Doughty R.N., Whalley G.A., Walsh H.A., et al. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 2004;109:201-206.
  17. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006;166:659-666.
  18. Lechat P., Escolano S., Golmard J.L., et al. Prognostic value of bisoprolol-induced hemodynamic effects in Heart Failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation 1997;96:2197-2205.
  19. van de Ven L.L., Van Veldhuisen D.J., Goulder M., et al. The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure. Int J Cardiol 2010;144:59-63.
  20. Hoshikawa E., Matsumura Y., Kubo T., et al. Effect of left ventricular reverse remodeling on long-term prognosis after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta blockers in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2011;107:1065-1070.
  21. Düngen H.D., Apostolovic S., Inkrot S., et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail 2011;13:670-680.
  22. Bristow M.R., Gilbert E.M., Abraham W.T., et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94:2807-2816.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.